The aim of this study was to evaluate the efficiency of sulphurous thermal water in the treatment of chronic rhinosinusitis (CRS). Eighty patients with CRS were included and randomly assigned into two groups. Patients underwent a 12-day course of warm vapour inhalations and nasal irrigations with sulphurous thermal water in group A, and a physiological solution in group B. Compared with group B, in group A the results were as follows: serum concentration of IgE was significantly lower (p < 0.05) 12 days (76.27 ± 26.3 mg/dl vs. 97.44 ± 45.4) and 3 months after the beginning of the treatment (75.48 ± 26.1 mg/dl vs. 98.37 ± 41.4); IgA titers were not significantly higher 12 days (231.09 ± 120.3 mg/dl vs. 220.44 ± 114.4 mg/dl) and 3 months after the beginning of the treatment (235.44 ± 118.5 mg/dl vs. 214.51 ± 111.8 mg/dl); VAS scores were significantly (p < 0.05) improved at 12 days (1.7 ± 0.18 vs. 6.9 ± 0.51) and 3 months after the start (1.8 ± 0.22 vs. 7.1 ± 0.59); NMTT was normal at 12 days (11.54 ± 1.59 min vs. 17.38 ± 1.83 min) and 3 months after the beginning of the treatment (11.46 ± 2.07 min vs. 17.43 ± 2.01 min); total nasal resistances were significantly (p < 0.05) decreased at 12 days and 3 months. Our results indicate the efficiency and applicability of sulphurous thermal water in the treatment of CRS.
Sulphurous thermal water inhalations in the treatment of chronic rhinosinusitis
GUASTINI, LUCA;
2010-01-01
Abstract
The aim of this study was to evaluate the efficiency of sulphurous thermal water in the treatment of chronic rhinosinusitis (CRS). Eighty patients with CRS were included and randomly assigned into two groups. Patients underwent a 12-day course of warm vapour inhalations and nasal irrigations with sulphurous thermal water in group A, and a physiological solution in group B. Compared with group B, in group A the results were as follows: serum concentration of IgE was significantly lower (p < 0.05) 12 days (76.27 ± 26.3 mg/dl vs. 97.44 ± 45.4) and 3 months after the beginning of the treatment (75.48 ± 26.1 mg/dl vs. 98.37 ± 41.4); IgA titers were not significantly higher 12 days (231.09 ± 120.3 mg/dl vs. 220.44 ± 114.4 mg/dl) and 3 months after the beginning of the treatment (235.44 ± 118.5 mg/dl vs. 214.51 ± 111.8 mg/dl); VAS scores were significantly (p < 0.05) improved at 12 days (1.7 ± 0.18 vs. 6.9 ± 0.51) and 3 months after the start (1.8 ± 0.22 vs. 7.1 ± 0.59); NMTT was normal at 12 days (11.54 ± 1.59 min vs. 17.38 ± 1.83 min) and 3 months after the beginning of the treatment (11.46 ± 2.07 min vs. 17.43 ± 2.01 min); total nasal resistances were significantly (p < 0.05) decreased at 12 days and 3 months. Our results indicate the efficiency and applicability of sulphurous thermal water in the treatment of CRS.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
